Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer

Journal of Urology

Volumn 174, Issue 1, 2005, Pages 140-142

  Appu, Sree ^a,b,c   Lawrentschuk, Nathan ^a,c,d   Grills, Richard J ^a   Neerhut, Greg ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GEELONG HOSPITAL   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d NONE   (Australia)

Author keywords

Cyproterone acetate; Gonadorelin; Prostate; Prostatic neoplasms; Testosterone

Indexed keywords

CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; TREATMENT OUTCOME;

EID: 20444480172     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000161591.86721.e5     Document Type: Article

References (20)

1. Schulze, H. and Senge, T.: Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol, 144: 934, 1990
2. Scaletscky, R. and Smith, J. A.: Disease flare with gonadotrophin- releasing hormone (GnRH) analogues. How serious is it? Drug Saf, 8: 265, 1993
3. Goldenberg, S. L. and Bruchovsky, N.: Use of cyproterone acetate in prostate cancer. Urol Clin North Am, 18: 111, 1991
4. Thorpe, S. C., Azmatullah, S., Fellows, G. J., Gingell, J. C. and O'Boyle, P. J.: A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol, 29: 47, 1996
5. Ostri, P., Bonnesen, T., Nilsson, T. and Frimodt-Moller, C.: Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial. Urol Int, 46: 167, 1991
6. de Voogt, H. J.: The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate Suppl, 4: 91, 1992
7. Schroder, F. H., Whelan, P., de Reijke, T. M., Kurth, K. H., Pavone-Macaluso, M., Mattelaer, J. et al: Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol, 45: 457, 2004
8. Eaton, A. C. and McGuire, N.: Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet, 2: 1336, 1983
9. Boccon-Gibod, L., Laudat, M. H., Dugue, M. A. and Steg, A.: Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol, 12: 400, 1986
10. Klign, J. G., de Voogt, H. J., Schroder, F. H. and de Jong, F. H.: Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet, 2: 493, 1985
11. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med, 311: 1281, 1984
12. Marks, L. S.: Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology, 62: 36, 2003
13. Thompson, I. M., Zeidman, E. J. and Rodriguez, F. R.: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol, 144: 1479, 1990
14. Labrie, F., Dupont, A., Belanger, A., Cusan, L., Lacourciere, Y., Monfette, G. et al: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med, 5: 267, 1982
15. Schroeder, F. H., Lock, T. M. T. W., Chadha, D. R., Debruyne, F. M., Karthaus, H. F. M., de Jong, F. H. et al: Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol, 137: 912, 1987
16. Bruchovsky, N., Goldenberg, S. L., Akakura, K. and Rennie, P. S.: Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer, 72: 1685, 1993
17. Goldenberg, S. L., Bruchovsky, N., Rennie, P. S. and Coppin, C. M.: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol, 140: 1460, 1988
18. Barradell, L. B. and Faulds, D.: Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging, 5: 59, 1994
19. Lin, B. J., Chen, K. K., Chen, M. T. and Chang, L. S.: The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology, 43: 834, 1994
20. Huggins, C., Stevens, R. and Hodges, C.: Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg, 43: 209, 1941